Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
National
May 16, 2021
ISLAMABAD: The Rawalpindi Ring Road controversy erupted because the government had refused to get a $400 million concessional loan from the Asian Infrastructure Investment Bank (AIIB) and preferred to construct it through half-baked public-private partnership, The News has learnt.
In a story published in this newspaper, this correspondent had written that “the AIIB committed $1 billion concessional loan for three important projects including $400 million for Rawalpindi Ring Road (RRR) project connecting the twin cities of Islamabad and Rawalpindi and two projects for Lahore including Waste Water Treatment and Urban/Environmental Development Project.
It had been written that “the talks with the AIIB were held in 2018 but now more than two years have passed and the AIIB may withdraw this loan facility. All relevant official documents available with The News revealed that three projects are in the pipeline but now things are quite unclear where no one exac
The decision was taken on Saturday during a special session of the National Command and Operation Center (NCOC) chaired by Federal Minister for Planning, Development and Special Initiatives Asad Umar, reports Xinhua news agency. Acco
Students in a classroom wearing face masks during the Covid-19 pandemic. | Juan Obregon
Argentina’s decision to shut down schools has become the latest point of political conflict between the federal government and the Buenos Aires City government, run by the opposition, as the country heads into a second wave of Covid-19.
Buenos Aires City Mayor Horacio Rodríguez Larreta said that his administration will ask the Supreme Court for a protection measure to continue in-person school attendance in the country’s capital, a day after the government announced tighter restrictions in Greater Buenos Aires until the end of April.
Vera Therapeutics raised $47.9 million from its IPO to continue clinical development of its lead asset, a potential treatment for the kidney disease IgA nephropathy. But the company is joining a crowded field of companies aiming to develop a drug for the rare disorder.